EP
MRNA icon

Essential Partners’s Moderna MRNA Stock Holding History

Essential Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.75K Buy
+125
New +$6.47K ﹤0.01% 1274
2025
Q4 		– Sell
-3
Closed -$77 – 2868
2025
Q3 		$77 Buy
+3
New +$84 ﹤0.01% 2521

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Essential Partners's MRNA Position: Q2 2026 in Review

Essential Partners opened a new position in Moderna (MRNA) in Q2 2026: 125 shares worth $8.75K. The stake represents ﹤0.01% of the portfolio and ranks #1274 among its holdings. This is a return to the name: Essential Partners previously reported a position in MRNA as recently as Q3 2025.

Essential Partners first reported a position in MRNA in Q3 2025 and has held it in 2 quarters since. 780 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Essential Partners held 125 shares of Moderna worth $8.75K as of Q2 2026.
  • Moderna was a new Essential Partners position in Q2 2026.
  • Moderna made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1274 holding.
  • Essential Partners first reported a position in Moderna in Q3 2025 and has held it in 2 quarters since.
  • 780 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.